Use of CSF biomarkers in Alzheimer’s disease clinical trials

被引：0
|
作者：
K. Blennow
H. Zetterberg
机构：
[1] the Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Laboratory
[2] The Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Lab
[3] Sahlgrenska University Hospital,undefined
来源：
JNHA - The Journal of Nutrition, Health and Aging | 2009年 / 13卷
关键词：
Mild Cognitive Impairment; Lewy Body Dementia; BACE1 Inhibitor; Secretase Inhibitor; Mild Cognitive Impairment Case;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] fMRI: use in early Alzheimer's disease and in clinical trials
    Pihlajamiki, Maija
    Sperling, Reisa A.
    FUTURE NEUROLOGY, 2008, 3 (04) : 409 - 421
  • [42] Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease
    Dickerson B.C.
    Sperling R.A.
    NeuroRX, 2005, 2 (2): : 348 - 360
  • [43] Selection of subjects for clinical trials in Alzheimer’s disease and mild cognitive impairment with machine learning analysis of MRI and CSF biomarkers
    Javier Escudero
    John P Zajicek
    Emmanuel Ifeachor
    Trials, 12 (Suppl 1)
  • [44] Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease
    Wang, Yan
    Li, Fangyu
    Qin, Qi
    Li, Tingting
    Wang, Qi
    Li, Yan
    Li, Ying
    Jia, Jianping
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2025, 12 (04):
  • [45] An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
    Van Hulle, Carol
    Jonaitis, Erin M.
    Betthauser, Tobey J.
    Batrla, Richard
    Wild, Norbert
    Kollmorgen, Gwendlyn
    Andreasson, Ulf
    Okonkwo, Ozioma
    Bendlin, Barbara B.
    Asthana, Sanjay
    Carlsson, Cynthia M.
    Johnson, Sterling C.
    Zetterberg, Henrik
    Blennow, Kaj
    ALZHEIMERS & DEMENTIA, 2021, 17 (03) : 431 - 445
  • [46] CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment
    Blennow, K
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (05) : 661 - 672
  • [47] Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF
    Canevelli, Marco
    Bacigalupo, Ilaria
    Gervasi, Giuseppe
    Lacorte, Eleonora
    Massari, Marco
    Mayer, Flavia
    Vanacore, Nicola
    Cesari, Matteo
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [48] Recognizing Atypical Presentations of Alzheimer's Disease: The Importance of CSF Biomarkers in Clinical Practice
    Paraskevas, George P. P.
    Constantinides, Vasilios C. C.
    Boufidou, Fotini
    Tsantzali, Ioanna
    Pyrgelis, Efstratios-Stylianos
    Liakakis, Georgios
    Kapaki, Elisabeth
    DIAGNOSTICS, 2022, 12 (12)
  • [49] Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials
    Siemers, Eric
    DeMattos, Ronald B.
    May, Patrick C.
    Dean, Robert A.
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 81 - 89
  • [50] Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
    Ossenkoppele, Rik
    van der Kant, Rik
    Hansson, Oskar
    LANCET NEUROLOGY, 2022, 21 (08): : 726 - 734
12345